Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy

OncoImmunology

Volumn 3, Issue 2, 2014, Pages

  Issa Nummer, Yasmin ^a   Loibl, Sibylle ^a   von Minckwitz, Gunter ^a   Denkert, Carsten ^b  

^a GERMAN BREAST GROUP   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Biological marker; Breast cancer; Neoadjuvant chemotherapy; Response predictor

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ARTICLE; B LYMPHOCYTE; BREAST ADENOCARCINOMA; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; DISEASE MARKER; DRUG EFFICACY; HUMAN; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84899069154     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27926     Document Type: Article

References (10)

1. von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Huober J, et al. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2013; 31:3623-30; PMID:24002511; http://dx.doi. org/10.1200/JCO.2012.45.0940.
2. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20:1456-66; PMID:11896092; http://dx.doi.org/10.1200/JCO.20.6.1456.
3. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28:105-13; PMID:19917869; http://dx.doi. org/10.1200/JCO.2009.23.7370.
4. Issa-Nummer Y, Darb-Esfahani S, Loibl S, Kunz G, Nekljudova V, Schrader I, Sinn BV, Ulmer HU, Kronenwett R, Just M, et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer -a substudy of the neoadjuvant GeparQuinto trial. PLoS One 2013; 8:e79775; PMID:24312450; http://dx.doi.org/10.1371/journal.pone.0079775.
5. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8:151-60; PMID:21364688; http://dx.doi.org/10.1038/nrclinonc.2010.223.
6. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29:1949-55; PMID:21483002; http://dx.doi. org/10.1200/JCO.2010.30.5037.
7. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013; 31:860-7; PMID:23341518; http://dx.doi.org/10.1200/JCO.2011.41.0902.
8. Denkert C, Loibl S, Salat C, Sinn BV, Schem C, Endris V, Klare P, Schmitt WD, Blohmer J-U, Weichert W, et al. Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66). SABCS 2013 abstr S1-06.
9. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8:59-73; PMID:18097448; http://dx.doi.org/10.1038/nri2216.
10. Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C, Loi S. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res 2013; 19:28-33; PMID:23258741; http://dx.doi. org/10.1158/1078-0432.CCR-11-2701.